These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 27460432)

  • 1. Effect of Metformin Use on Survival Outcomes in Patients With Metastatic Renal Cell Carcinoma.
    Hamieh L; McKay RR; Lin X; Moreira RB; Simantov R; Choueiri TK
    Clin Genitourin Cancer; 2017 Apr; 15(2):221-229. PubMed ID: 27460432
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metformin Use and Outcome of Sunitinib Treatment in Patients With Diabetes and Metastatic Renal Cell Carcinoma.
    Keizman D; Ish-Shalom M; Sella A; Gottfried M; Maimon N; Peer A; Hammers H; Eisenberger MA; Sinibaldi V; Neiman V; Rosenbaum E; Sarid D; Mermershtain W; Rouvinov K; Berger R; Carducci MA
    Clin Genitourin Cancer; 2016 Oct; 14(5):420-425. PubMed ID: 27211307
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Heterogeneity of Patients With Intermediate-Prognosis Metastatic Renal Cell Carcinoma Treated With Sunitinib.
    Sella A; Michaelson MD; Matczak E; Simantov R; Lin X; Figlin RA
    Clin Genitourin Cancer; 2017 Apr; 15(2):291-299.e1. PubMed ID: 27638198
    [TBL] [Abstract][Full Text] [Related]  

  • 4. First-line sunitinib versus pazopanib in metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium.
    Ruiz-Morales JM; Swierkowski M; Wells JC; Fraccon AP; Pasini F; Donskov F; Bjarnason GA; Lee JL; Sim HW; Sliwczynsk A; Ptak-Chmielewska A; Teter Z; Beuselinck B; Wood LA; Yuasa T; Pezaro C; Rini BI; Szczylik C; Choueiri TK; Heng DY
    Eur J Cancer; 2016 Sep; 65():102-8. PubMed ID: 27487293
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium.
    Heng DY; Wells JC; Rini BI; Beuselinck B; Lee JL; Knox JJ; Bjarnason GA; Pal SK; Kollmannsberger CK; Yuasa T; Srinivas S; Donskov F; Bamias A; Wood LA; Ernst DS; Agarwal N; Vaishampayan UN; Rha SY; Kim JJ; Choueiri TK
    Eur Urol; 2014 Oct; 66(4):704-10. PubMed ID: 24931622
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proton Pump Inhibitors and Survival Outcomes in Patients With Metastatic Renal Cell Carcinoma.
    Lalani AA; McKay RR; Lin X; Simantov R; Kaymakcalan MD; Choueiri TK
    Clin Genitourin Cancer; 2017 Dec; 15(6):724-732. PubMed ID: 28645482
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sunitinib in Patients With Metastatic Renal Cell Carcinoma: Clinical Outcome According to International Metastatic Renal Cell Carcinoma Database Consortium Risk Group.
    Rini BI; Hutson TE; Figlin RA; Lechuga MJ; Valota O; Serfass L; Rosbrook B; Motzer RJ
    Clin Genitourin Cancer; 2018 Aug; 16(4):298-304. PubMed ID: 29853320
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic impact of baseline serum C-reactive protein in patients with metastatic renal cell carcinoma (RCC) treated with sunitinib.
    Beuselinck B; Vano YA; Oudard S; Wolter P; De Smet R; Depoorter L; Teghom C; Karadimou A; Zucman-Rossi J; Debruyne PR; Van Poppel H; Joniau S; Lerut E; Strijbos M; Dumez H; Paridaens R; Van Calster B; Schöffski P
    BJU Int; 2014 Jul; 114(1):81-9. PubMed ID: 24215209
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcome of Patients With Metastatic Chromophobe Renal Cell Carcinoma Treated With Sunitinib.
    Keizman D; Sarid D; Lee JL; Sella A; Gottfried M; Hammers H; Eisenberger MA; Carducci MA; Sinibaldi V; Neiman V; Rosenbaum E; Peer A; Neumann A; Mermershtain W; Rouvinov K; Berger R; Yildiz I
    Oncologist; 2016 Oct; 21(10):1212-1217. PubMed ID: 27382030
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is there a "Trial Effect" on Outcome of Patients with Metastatic Renal Cell Carcinoma Treated with Sunitinib?
    Keizman D; Rouvinov K; Sella A; Gottfried M; Maimon N; Kim JJ; Eisenberger MA; Sinibaldi V; Peer A; Carducci MA; Mermershtain W; Leibowitz-Amit R; Weitzen R; Berger R
    Cancer Res Treat; 2016 Jan; 48(1):281-7. PubMed ID: 25761478
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sunitinib (Sutent): a novel agent for the treatment of metastatic renal cell carcinoma.
    Chouhan JD; Zamarripa DE; Lai PH; Oramasionwu CU; Grabinski JL
    J Oncol Pharm Pract; 2007 Mar; 13(1):5-15. PubMed ID: 17621562
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Active smoking may negatively affect response rate, progression-free survival, and overall survival of patients with metastatic renal cell carcinoma treated with sunitinib.
    Keizman D; Gottfried M; Ish-Shalom M; Maimon N; Peer A; Neumann A; Hammers H; Eisenberger MA; Sinibaldi V; Pili R; Hayat H; Kovel S; Sella A; Boursi B; Weitzen R; Mermershtain W; Rouvinov K; Berger R; Carducci MA
    Oncologist; 2014 Jan; 19(1):51-60. PubMed ID: 24309979
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Statins and survival outcomes in patients with metastatic renal cell carcinoma.
    McKay RR; Lin X; Albiges L; Fay AP; Kaymakcalan MD; Mickey SS; Ghoroghchian PP; Bhatt RS; Kaffenberger SD; Simantov R; Choueiri TK; Heng DY
    Eur J Cancer; 2016 Jan; 52():155-62. PubMed ID: 26687834
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of sorafenib versus sunitinib as first-line treatment in patients with metastatic renal cell carcinoma: largest single-center retrospective analysis.
    Sheng X; Chi Z; Cui C; Si L; Li S; Tang B; Mao L; Lian B; Wang X; Yan X; Guo J
    Oncotarget; 2016 May; 7(19):27044-54. PubMed ID: 26894858
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Angiotensin system inhibitors and survival in patients with metastatic renal cell carcinoma treated with VEGF-targeted therapy: A pooled secondary analysis of clinical trials.
    Sorich MJ; Kichenadasse G; Rowland A; Woodman RJ; Mangoni AA
    Int J Cancer; 2016 May; 138(9):2293-9. PubMed ID: 26685869
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of Second-Line Targeted Therapy Dose Intensity on Patients With Metastatic Renal Cell Carcinoma.
    Shirotake S; Yasumizu Y; Ito K; Masunaga A; Ito Y; Miyazaki Y; Hagiwara M; Kanao K; Mikami S; Nakagawa K; Momma T; Masuda T; Asano T; Oyama M; Tanaka N; Mizuno R; Oya M
    Clin Genitourin Cancer; 2016 Dec; 14(6):e575-e583. PubMed ID: 27102405
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The impact of tumor burden characteristics in patients with metastatic renal cell carcinoma treated with sunitinib.
    Basappa NS; Elson P; Golshayan AR; Wood L; Garcia JA; Dreicer R; Rini BI
    Cancer; 2011 Mar; 117(6):1183-9. PubMed ID: 20960527
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Experience with sunitinib treatment for metastatic renal cell carcinoma in a large cohort of Israeli patients: outcome and associated factors.
    Livne-Segev D; Gottfried M; Maimon N; Peer A; Neumann A; Hayat H; Kovel S; Sella A; Mermershtain W; Rouvinov K; Boursi B; Weitzen R; Berger R; Keizman D
    Isr Med Assoc J; 2014 Jun; 16(6):347-51. PubMed ID: 25058995
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative efficacy of sunitinib versus sorafenib as first-line treatment for patients with metastatic renal cell carcinoma.
    Park SJ; Lee JL; Park I; Park K; Ahn Y; Ahn JH; Lee DH; Ahn S; Song C; Hong JH; Kim CS; Ahn H
    Chemotherapy; 2012; 58(6):468-74. PubMed ID: 23548259
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development and validation of a prognostic model in patients with metastatic renal cell carcinoma treated with sunitinib: a European collaboration.
    Bamias A; Tzannis K; Beuselinck B; Oudard S; Escudier B; Diosynopoulos D; Papazisis K; Lang H; Wolter P; de Guillebon E; Stravodimos K; Chrisofos M; Fountzilas G; Elaidi RT; Dimopoulos MA; Bamia C
    Br J Cancer; 2013 Jul; 109(2):332-41. PubMed ID: 23807171
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.